Quintiles Report Addresses Importance of Market Access in Europe

Quintiles Report Addresses Importance of Market Access in Europe

QuintilesLaura Wilson, +44 118 450 8392Media RelationsorGreg Connors, +1-919-998-2000Investor Relations

With payers playing an increasingly critical role in physician prescribing practices across Europe, regulatory approval is no longer the end game of drug development. Market access is now the primary driver of product success, requiring that payer priorities be integrated at every stage of product strategy. How to navigate this new world is the topic of a new Quintiles white paper titled

The paper advocates early planning to ensure the right data is gathered in clinical trials; collection of real-world data for Health Technology Assessment (HTA) submission; communications at a global, national and local basis; and better collaboration and joint working between stakeholders.

“In this complex environment, all stakeholders need to work closely from very early in clinical strategy development, right through to commercialization and long-term, real-world outcomes data collection,” said Janice Haigh, Consulting Practice Leader, Market Access Europe, one of the white paper’s authors. “It’s not just a matter of reworking methodologies to make the product seem more valuable. It requires a fundamental shift in approach, with a genuine focus on unmet need. Biopharma companies need to collect the right level of evidence based on the right endpoints to provide better health outcomes to patients and deliver value to payers.”

In addition to Haigh, Louise Parmenter, Senior Director of Global Strategic Operations, Quintiles Outcome, and Chris Pepler, Head of Commercial Solutions, Europe, authored the paper. Market access was a major topic of interest at ISPOR’s 15 Annual European Congress held in Berlin from 3-7 November. Quintiles was represented at multiple workshops, issue panels, podium and poster presentations, spanning topics such as , , and .

Alesia Kalbasko, who now works for Quintiles Consulting, was named a winner in the Student Podium Presentation category for her , completed during her time at Erasmus University.

Quintiles is the world’s leading provider of biopharmaceutical services. With a network of more than 27,000 professionals working in more than 80 countries, we have helped develop or commercialize all of the top 50 best selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, we help biopharmaceutical and health sciences customers navigate the increasingly complex landscape with more predictability to enable better outcomes.

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.